Momenta Pharmaceuticals (MNTA) 18.62 $MNTA
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 21, 12:45PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
TTS: 14.52 (-0.33), HAS: 71.73 (-1.82), AMSC: 10.40 (+1.20), ECHO: 33.39 (+1.37), LJPC: 23.04 (+1.22), RMBS: 14.40 (+0.22), TGLS: 11.98 (+0.70), VLTC: 15.14 (-1.04), MNTA: 18.62 (+0.56), SPKE: 12.97 (+0.09), ROVI: 19.46 (+0.10)
Momenta Pharmaceuticals Has Returned 49.2% Since SmarTrend Recommendation (MNTA)
Comtex SmarTrend(R) - Tue Apr 21, 11:24AM CDT
SmarTrend identified an Uptrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on February 18th, 2015 at $12.52. In approximately 2 months, Momenta Pharmaceuticals has returned 49.18% as of today's recent price of $18.67.
MNTA: 18.62 (+0.56)
Teva Bids $40 Billion For Mylan, But May Need More
at Investor's Business Daily - Tue Apr 21, 10:35AM CDT
Israeli drug giant Teva Pharmaceutical Industries (TEVA) made its long-awaited bid for competitor Mylan on Tuesday, offering $82 a share, or $40.1 billion. Both stocks rose on the news. Teva's proposal, half cash and half stock, was unsolicited by...
PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)
A Look at the Health of the HealthCare Sector: Complementary Research on Horizon Pharma, Enzon Pharmaceuticals, Momenta Pharmaceuticals, Athersys, and Pernix Therapeutics
PR Newswire - Tue Apr 21, 9:46AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ENZN: 1.70 (+0.20), PTX: 7.44 (-0.05), HZNP: 30.96 (+0.10), ATHX: 1.34 (+0.01), MNTA: 18.62 (+0.56)
Looking For Action? S&P 1500 Most Volatile Stocks
Bespoke Investment Group - at Seeking Alpha - Tue Apr 21, 3:30AM CDT
For traders with a short-term time horizon who are looking for big moves over a short period, we have updated our list of the 50 S&P 1500 stocks trading above $10 that have the largest intraday high-low ranges (based on the average percent spread...
CRR: 33.68 (-0.12), NBR: 15.05 (+0.68), BCEI: 24.50 (-0.20), LL: 33.86 (+0.50), PTEN: 21.01 (+0.68), MNTA: 18.62 (+0.56), HOS: 20.11 (-0.89), KOP: 22.68 (+0.05), DO: 30.07 (-0.02), BBG: 9.80 (-0.41), SGY: 16.54 (-0.83), FTK: 15.56 (+0.10), SPN: 23.84 (+0.41), ROVI: 19.46 (+0.10), WPX: 13.40 (+0.16), AKRX: 53.70 (-1.69), MCF: 20.44 (-0.02), ZEUS: 10.79 (-0.32), LGND: 87.71 (-0.58), DEPO: 27.14 (+0.65), CCRN: 11.10 (+0.01), ESV: 24.03 (+0.13), ANIP: 69.79 (+1.24), SGNT: 25.43 (-0.29), PDCE: 55.02 (-0.03), NE: 16.18 (+0.14), UIHC: 20.78 (+0.18), TNGO: 14.04 (-0.16), SGMS: 12.48 (+0.25), GIFI: 15.33 (+0.25), TDW: 24.66 (-0.59), CENX: 13.28 (+0.17), UNT: 30.38 (+0.43), RIG: 16.85 (-0.18), SPOK: 20.73 (+0.23), GPRE: 30.59 (-0.02), SYRG: 12.37 (+0.06), GEOS: 20.76 (+0.57), CBM: 42.07 (-0.65), SM: 55.21 (+1.23), TESO: 12.48 (+0.09), ROSE: 22.02 (-0.50), RGEN: 33.37 (+0.51), VDSI: 25.11 (-0.58), SKYW: 14.22 (unch), GLF: 13.77 (-0.11), SLCA: 36.94 (+0.70), RDC: 19.42 (-0.13), EHTH: 11.44 (+0.07)
Momenta Presents Key Glatopa(TM) (glatiramer acetate injection) Data at American Academy of Neurology Annual Meeting
GlobeNewswire - Mon Apr 20, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today presented new data from studies conducted as part of the ANDA submission for once daily Glatopa (glatiramer acetate injection) at the 67th American Academy of Neurology (AAN) Annual Meeting in Washington D.C. The posters presented provide examples of a selection of methods the Company utilized to show the equivalence of Glatopa and once daily COPAXONE 20 mg.
MNTA: 18.62 (+0.56)
Novartis and Momenta Get FDA Nod For Generic Copaxone - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 4:10PM CDT
Novartis AG (NVS) announced that its generic arm has received FDA approval for Glatopa, the first generic version of Teva Pharmaceuticals' (TEVA) multiple sclerosis drug, Copaxone.
MNK: 122.95 (-2.22), TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)
FDA approves generic version of top-selling MS drug Copaxone
AP - Fri Apr 17, 12:17PM CDT
NEW YORK (AP) — Two drugmakers are preparing to sell a lower-cost version of Copaxone, the world's most-widely used drug for multiple sclerosis.
TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)
Strong On High Relative Volume: Momenta Pharmaceuticals (MNTA)
at The Street - Fri Apr 17, 9:10AM CDT
Trade-Ideas LLC identified Momenta Pharmaceuticals (MNTA) as a strong on high relative volume candidate
MNTA: 18.62 (+0.56)
Momenta Pharmaceuticals Inc. (MNTA) in Focus: Stock Jumps 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 8:21AM CDT
Momenta Pharmaceuticals Inc. (MNTA) was a big mover last session, as the company saw its shares rise over 6% on the day.
MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)
Momenta Pharmaceuticals Announces Data Presentations on Glatopa(TM) (glatiramer acetate injection) at the American Academy of Neurology's (AAN) 2015 Annual Meeting
GlobeNewswire - Fri Apr 17, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the upcoming presentation of two posters comparing gene expression profiles and additional methods used to show equivalence between Glatopa and daily COPAXONE 20 mg (glatiramer acetate injection). The posters will be presented at the 67 AAN Annual Meeting taking place April 18 - 25, 2015 in Washington, D.C.
MNTA: 18.62 (+0.56)
Momenta, Novartis get FDA OK
at Investor's Business Daily - Thu Apr 16, 5:43PM CDT
Sandoz, the generic division of Novartis (NVS), and its biotech partner Momenta Pharmaceuticals (MNTA) won approval from the FDA for the first generic version of Copaxone, a widely used multiple-sclerosis drug. The FDA denied a request by Copaxone's...
TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)
Look for Shares of Momenta Pharmaceuticals to Potentially Pullback after Yesterday's 6.09% Rise
Comtex SmarTrend(R) - Thu Apr 16, 4:16PM CDT
Momenta Pharmaceuticals (NASDAQ:MNTA) traded in a range yesterday that spanned from a low of $16.03 to a high of $20.43. Yesterday, the shares gained 6.1%, which took the trading range above the 3-day high of $16.53 on volume of 8.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MNTA: 18.62 (+0.56)
Why Momenta Pharmaceuticals Inc. Shares Are Surging Higher
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 16, 4:15PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Momenta Pharmaceuticals shares jumped...
TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)
Momenta, Novartis Win FDA Nod For Generic Copaxone
at Investor's Business Daily - Thu Apr 16, 1:39PM CDT
Sandoz, the generics division of Novartis (NVS), and its biotech partner Momenta Pharmaceuticals won FDA approval on Thursday for the first generic version of popular multiple-sclerosis drug Copaxone. The FDA denied a citizens' petition by Copaxone's...
MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)
FDA clears generic version of Teva's Copaxone
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 12:07PM CDT
TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)
Momenta Pharmaceuticals Announces Conference Call Details Regarding FDA Approval for Glatopa(TM) (glatiramer acetate injection)
GlobeNewswire - Thu Apr 16, 11:54AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will conduct a conference call to discuss the approval of Glatopa(TM) (glatiramer acetate injection, formerly M356) 20mg/mL, the first substitutable generic for COPAXONE.
MNTA: 18.62 (+0.56)
Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
GlobeNewswire - Thu Apr 16, 11:31AM CDT
-- First generic multiple sclerosis product approved in the United States
MNTA: 18.62 (+0.56)
GPhA Launches Biosimilars Council, New Industry Group Will Educate and Advocate for Patient Access to Safe, Affordable Lifesaving Medicines
PR Newswire - Thu Apr 16, 11:17AM CDT
The Generic Pharmaceutical Association (GPhA) is pleased to announce today's launch of the Biosimilars Council, a division of GPhA.
MNTA: 18.62 (+0.56)
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 21, 12:45PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
TTS: 14.52 (-0.33), HAS: 71.73 (-1.82), AMSC: 10.40 (+1.20), ECHO: 33.39 (+1.37), LJPC: 23.04 (+1.22), RMBS: 14.40 (+0.22), TGLS: 11.98 (+0.70), VLTC: 15.14 (-1.04), MNTA: 18.62 (+0.56), SPKE: 12.97 (+0.09), ROVI: 19.46 (+0.10)
Momenta Pharmaceuticals Has Returned 49.2% Since SmarTrend Recommendation (MNTA)
Comtex SmarTrend(R) - Tue Apr 21, 11:24AM CDT
SmarTrend identified an Uptrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on February 18th, 2015 at $12.52. In approximately 2 months, Momenta Pharmaceuticals has returned 49.18% as of today's recent price of $18.67.
MNTA: 18.62 (+0.56)
Teva Bids $40 Billion For Mylan, But May Need More
at Investor's Business Daily - Tue Apr 21, 10:35AM CDT
Israeli drug giant Teva Pharmaceutical Industries (TEVA) made its long-awaited bid for competitor Mylan on Tuesday, offering $82 a share, or $40.1 billion. Both stocks rose on the news. Teva's proposal, half cash and half stock, was unsolicited by...
PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)
A Look at the Health of the HealthCare Sector: Complementary Research on Horizon Pharma, Enzon Pharmaceuticals, Momenta Pharmaceuticals, Athersys, and Pernix Therapeutics
PR Newswire - Tue Apr 21, 9:46AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ENZN: 1.70 (+0.20), PTX: 7.44 (-0.05), HZNP: 30.96 (+0.10), ATHX: 1.34 (+0.01), MNTA: 18.62 (+0.56)
Looking For Action? S&P 1500 Most Volatile Stocks
Bespoke Investment Group - at Seeking Alpha - Tue Apr 21, 3:30AM CDT
For traders with a short-term time horizon who are looking for big moves over a short period, we have updated our list of the 50 S&P 1500 stocks trading above $10 that have the largest intraday high-low ranges (based on the average percent spread...
CRR: 33.68 (-0.12), NBR: 15.05 (+0.68), BCEI: 24.50 (-0.20), LL: 33.86 (+0.50), PTEN: 21.01 (+0.68), MNTA: 18.62 (+0.56), HOS: 20.11 (-0.89), KOP: 22.68 (+0.05), DO: 30.07 (-0.02), BBG: 9.80 (-0.41), SGY: 16.54 (-0.83), FTK: 15.56 (+0.10), SPN: 23.84 (+0.41), ROVI: 19.46 (+0.10), WPX: 13.40 (+0.16), AKRX: 53.70 (-1.69), MCF: 20.44 (-0.02), ZEUS: 10.79 (-0.32), LGND: 87.71 (-0.58), DEPO: 27.14 (+0.65), CCRN: 11.10 (+0.01), ESV: 24.03 (+0.13), ANIP: 69.79 (+1.24), SGNT: 25.43 (-0.29), PDCE: 55.02 (-0.03), NE: 16.18 (+0.14), UIHC: 20.78 (+0.18), TNGO: 14.04 (-0.16), SGMS: 12.48 (+0.25), GIFI: 15.33 (+0.25), TDW: 24.66 (-0.59), CENX: 13.28 (+0.17), UNT: 30.38 (+0.43), RIG: 16.85 (-0.18), SPOK: 20.73 (+0.23), GPRE: 30.59 (-0.02), SYRG: 12.37 (+0.06), GEOS: 20.76 (+0.57), CBM: 42.07 (-0.65), SM: 55.21 (+1.23), TESO: 12.48 (+0.09), ROSE: 22.02 (-0.50), RGEN: 33.37 (+0.51), VDSI: 25.11 (-0.58), SKYW: 14.22 (unch), GLF: 13.77 (-0.11), SLCA: 36.94 (+0.70), RDC: 19.42 (-0.13), EHTH: 11.44 (+0.07)
Momenta Presents Key Glatopa(TM) (glatiramer acetate injection) Data at American Academy of Neurology Annual Meeting
GlobeNewswire - Mon Apr 20, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today presented new data from studies conducted as part of the ANDA submission for once daily Glatopa (glatiramer acetate injection) at the 67th American Academy of Neurology (AAN) Annual Meeting in Washington D.C. The posters presented provide examples of a selection of methods the Company utilized to show the equivalence of Glatopa and once daily COPAXONE 20 mg.
MNTA: 18.62 (+0.56)
Novartis and Momenta Get FDA Nod For Generic Copaxone - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 4:10PM CDT
Novartis AG (NVS) announced that its generic arm has received FDA approval for Glatopa, the first generic version of Teva Pharmaceuticals' (TEVA) multiple sclerosis drug, Copaxone.
MNK: 122.95 (-2.22), TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)
FDA approves generic version of top-selling MS drug Copaxone
AP - Fri Apr 17, 12:17PM CDT
NEW YORK (AP) — Two drugmakers are preparing to sell a lower-cost version of Copaxone, the world's most-widely used drug for multiple sclerosis.
TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)
Strong On High Relative Volume: Momenta Pharmaceuticals (MNTA)
at The Street - Fri Apr 17, 9:10AM CDT
Trade-Ideas LLC identified Momenta Pharmaceuticals (MNTA) as a strong on high relative volume candidate
MNTA: 18.62 (+0.56)
Momenta Pharmaceuticals Inc. (MNTA) in Focus: Stock Jumps 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 8:21AM CDT
Momenta Pharmaceuticals Inc. (MNTA) was a big mover last session, as the company saw its shares rise over 6% on the day.
MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)
Momenta Pharmaceuticals Announces Data Presentations on Glatopa(TM) (glatiramer acetate injection) at the American Academy of Neurology's (AAN) 2015 Annual Meeting
GlobeNewswire - Fri Apr 17, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the upcoming presentation of two posters comparing gene expression profiles and additional methods used to show equivalence between Glatopa and daily COPAXONE 20 mg (glatiramer acetate injection). The posters will be presented at the 67 AAN Annual Meeting taking place April 18 - 25, 2015 in Washington, D.C.
MNTA: 18.62 (+0.56)
Momenta, Novartis get FDA OK
at Investor's Business Daily - Thu Apr 16, 5:43PM CDT
Sandoz, the generic division of Novartis (NVS), and its biotech partner Momenta Pharmaceuticals (MNTA) won approval from the FDA for the first generic version of Copaxone, a widely used multiple-sclerosis drug. The FDA denied a request by Copaxone's...
TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)
Look for Shares of Momenta Pharmaceuticals to Potentially Pullback after Yesterday's 6.09% Rise
Comtex SmarTrend(R) - Thu Apr 16, 4:16PM CDT
Momenta Pharmaceuticals (NASDAQ:MNTA) traded in a range yesterday that spanned from a low of $16.03 to a high of $20.43. Yesterday, the shares gained 6.1%, which took the trading range above the 3-day high of $16.53 on volume of 8.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MNTA: 18.62 (+0.56)
Why Momenta Pharmaceuticals Inc. Shares Are Surging Higher
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 16, 4:15PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Momenta Pharmaceuticals shares jumped...
TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)
Momenta, Novartis Win FDA Nod For Generic Copaxone
at Investor's Business Daily - Thu Apr 16, 1:39PM CDT
Sandoz, the generics division of Novartis (NVS), and its biotech partner Momenta Pharmaceuticals won FDA approval on Thursday for the first generic version of popular multiple-sclerosis drug Copaxone. The FDA denied a citizens' petition by Copaxone's...
MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)
FDA clears generic version of Teva's Copaxone
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 12:07PM CDT
TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)
Momenta Pharmaceuticals Announces Conference Call Details Regarding FDA Approval for Glatopa(TM) (glatiramer acetate injection)
GlobeNewswire - Thu Apr 16, 11:54AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will conduct a conference call to discuss the approval of Glatopa(TM) (glatiramer acetate injection, formerly M356) 20mg/mL, the first substitutable generic for COPAXONE.
MNTA: 18.62 (+0.56)
Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
GlobeNewswire - Thu Apr 16, 11:31AM CDT
-- First generic multiple sclerosis product approved in the United States
MNTA: 18.62 (+0.56)
GPhA Launches Biosimilars Council, New Industry Group Will Educate and Advocate for Patient Access to Safe, Affordable Lifesaving Medicines
PR Newswire - Thu Apr 16, 11:17AM CDT
The Generic Pharmaceutical Association (GPhA) is pleased to announce today's launch of the Biosimilars Council, a division of GPhA.
MNTA: 18.62 (+0.56)
